Compare Nasdaq100 ETF (QQQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Recursion Pharmaceuticals Inc — how do they compare? Nasdaq100 ETF trades at $702.44, while Recursion Pharmaceuticals Inc trades at $2.99 (market cap $1.63B). The key difference: Nasdaq100 ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QQQ | RXRX | |
|---|---|---|
52-Week High | $746.16 | $6.79 |
52-Week Low | $553.88 | $2.84 |
Market Cap | — | $1.63B |
Sector | — | Health |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $708.97, up 1.96% over the past 24 hours, with technical indicators signaling a bearish trend overall despite a neutral oscillator reading. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights institutional position adjustments and comparisons with competing tech-focused ETFs.
Outlook remains divided; potential exists from tech sector strength and AI-driven growth, but risks include high concentration in tech stocks and market volatility. Investors should weigh the bearish technical signals against long-term growth prospects in the Nasdaq-100 index.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
